EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY-NC-ND 4.0

Corrigendum to “Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib” [Pharmaceut. Sci. Adv. 4, (2026), 100125]

Fuxun Huang, Peng Zhan, Xiujuan Shi, Yueyang Sun, Xingbo Song, Peilu Sun, Bo Liu

Pharmaceutical Science Advances · 2026-12 · 4 · 100154

DOI: 10.1016/j.pscia.2026.100154 ↗

Kurz gefasst

Korrektur in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Fuxun Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, Sh…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, Shandong, 250117, PR China.
  • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong Province, 250012, PR China.

Zitieren

APA

Huang, F., Zhan, P., Shi, X., Sun, Y., Song, X., Sun, P., & Liu, B. (2026). Corrigendum to “Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib” [Pharmaceut. Sci. Adv. 4, (2026), 100125]. Pharmaceutical Science Advances, 4, 100154. https://doi.org/10.1016/j.pscia.2026.100154

Vancouver

Huang F, Zhan P, Shi X, Sun Y, Song X, Sun P, et al. Corrigendum to “Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib” [Pharmaceut. Sci. Adv. 4, (2026), 100125]. Pharmaceutical Science Advances. 2026;4:100154. doi:10.1016/j.pscia.2026.100154

BibTeX
@article{Huang2026,
  author = {Huang, Fuxun and Zhan, Peng and Shi, Xiujuan and Sun, Yueyang and Song, Xingbo and Sun, Peilu and Liu, Bo},
  title = {Corrigendum to “Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib” [Pharmaceut. Sci. Adv. 4, (2026), 100125]},
  journal = {Pharmaceutical Science Advances},
  year = {2026},
  volume = {4},
  pages = {100154},
  doi = {10.1016/j.pscia.2026.100154}
}
Kostenlos starten →